A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer (POD1UM-304)
This study, called POD1UM-304, is testing a new treatment combination for advanced lung cancer. We're looking at adults who have non-small cell lung cancer that has spread (metastatic) and is either squamous or non-squamous type. Participants will receive standard chemotherapy, and some will also get a new drug called retifanlimab, while others will receive a placebo (a dummy drug). The main goal is to find out if adding retifanlimab helps people live longer. We'll also be checking how long it takes for the cancer to grow again, if the tumours shrink, and also whether the treatments cause any side effects. This is a Phase 3 study, which means it's a large trial to confirm if the new treatment is effective and safe before it can be widely used.
At a glance
What is this study about?
Imagine your body has tiny, clever defenders called the immune system that fight off infections and diseases. Sometimes, cancer cells can hide from these defenders. A new type of medicine, like the one being tested in this study (retifanlimab), aims to help your immune system find and fight these cancer cells better.
This study is for people in the UK who have a type of lung cancer called non-small cell lung cancer that has spread to other parts of the body. This is known as metastatic cancer. Doctors are trying to see if adding a new drug, retifanlimab, to the usual chemotherapy treatment can make a bigger difference than chemotherapy alone. This drug works by boosting your body's natural defences to attack the cancer.
The main thing researchers want to find out is whether people live longer with the new combination of treatments. They will also be carefully checking other important things, such as whether the tumours shrink, how long it takes for the cancer to grow again, and if there are any new or different side effects from the added drug. This is a vital step in discovering better ways to treat lung cancer.
Key takeaways
- This study is testing a new drug combination for advanced lung cancer.
- It aims to see if adding retifanlimab to chemotherapy helps people live longer.
- Participants will receive either the new drug or a dummy drug alongside chemotherapy.
- The study monitors how tumours respond and checks for any side effects.
- It's a Phase 3 study, meaning it's a critical step in assessing the new treatment.
Who may be eligible?
To be considered for this study, you need to be an adult, aged 18 or over. The study welcomes both men and women.
You must have been diagnosed with non-small cell lung cancer that has spread to other parts of your body. This cancer can be either of the 'squamous' or 'non-squamous' type. You will be starting your very first treatment for this advanced stage of lung cancer.
There will be specific medical checks to make sure your overall health is suitable for the treatments involved. Your hospital doctor will be able to tell you if the study is right for your particular situation.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have non-small cell lung cancer that has spread?
- Is this your first treatment for advanced lung cancer?
- Are you able to attend regular hospital appointments?
What does participation involve?
If you decide to take part, you'll be randomly assigned to one of two groups, like flipping a coin. One group will receive the standard chemotherapy plus the new drug (retifanlimab), and the other will get standard chemotherapy plus a dummy drug (placebo). Neither you nor your study doctor will know which group you are in, to make sure the results are fair.
Taking part will involve regular visits to the hospital for your treatments, which will be given as infusions (drips). During these visits, the study team will carry out medical checks, blood tests, and scans to see how you're responding to the treatment and to monitor your health. They will also ask you about any side effects you might be experiencing. The exact number of visits and the full duration of your participation will depend on how you respond to the treatment and what your study doctor recommends.
Potential risks and benefits
Locations (2)
- —UnverifiedCzechia
- —UnverifiedBulgaria
Common questions
What is non-small cell lung cancer?
It's the most common type of lung cancer, and it's given that name because of how the cells look under a microscope. It can be divided into squamous and non-squamous types.
What does 'metastatic' mean?
It means the cancer has spread from where it started in the lung to other parts of the body.
What is a 'Phase 3' study?
It's a large research study that compares a new treatment against existing ones to confirm if it's safe and works better.
What is a placebo?
A placebo is a 'dummy' treatment that looks exactly like the real drug but contains no active medicine. It helps researchers understand if the new drug itself is causing any effects.
Will I know if I'm getting the new drug or the placebo?
No, this is a 'double-blind' study, meaning neither you nor your doctors will know which treatment you are receiving until the study is over. This helps ensure the results are unbiased.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.